Newsroom
Category
December 13, 2022
Contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu SAN ANTONIO, Dec. 13, 2022 – With the U.S. grappling with an unprecedented opioid-related overdose crisis, The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded a $1.8 million grant from the National Institutes of Health to research peer recovery support services for […]
December 12, 2022
Studies of cell channels lead to therapeutic antibodies in clinical trials Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Dec. 12, 2022) — Jean X. Jiang, PhD, whose pioneering research has given rise to potential bone cancer and brain injury therapeutics currently under evaluation in clinical trials, will be inducted as a Fellow of the National […]
December 8, 2022
Contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu SAN ANTONIO, Dec. 8, 2022 – The UT Health San Antonio School of Dentistry secured nearly $35 million in total research grants awarded during its 2022 fiscal year, which ended Aug. 31, setting a new record for the school’s research program. “Our school’s research mission focuses on finding solutions to […]
December 7, 2022
UT Health San Antonio contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu Hill Country MHDD contact: Kelsi Wilmot, 830-370-6302, kelsi8310@hillcountry.org SAN ANTONIO, Dec. 7, 2022 – Be Well Texas, a statewide initiative of UT Health San Antonio, and Hill Country Mental Health & Developmental Disabilities Centers have entered into an agreement to provide substance use disorder (SUD) treatment […]
December 1, 2022
Four-year, $2 million federal grant will more than double rural providers Contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu SAN ANTONIO, Dec. 1, 2022 – UT Health San Antonio has received a four-year, $2 million federal grant to expand its substance use disorder response program, Be Well Texas, to the state’s 178 rural counties that have limited or […]
December 1, 2022
The AHEAD clinical trial will assess whether the new Alzheimer’s drug, lecanemab, can delay the onset of dementia in persons who are at high risk of developing the disease. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Dec. 1, 2022) — The Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, part of The University of Texas […]
